Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer

Modern Pathology

Volumn 23, Issue 5, 2010, Pages 763-772

  Radpour, Ramin ^a   Barekati, Zeinab ^a   Haghighi, Mahdi Montazer ^b   Kohler, Corina ^a   Asadollahi, Reza ^a   Torbati, Peyman Mohammadi ^c   Holzgreve, Wolfgang ^d   Zhong, Xiao Yan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Biomarker; Breast cancer; DNA methylation; MALDI TOF MS; Quantitative real time telomere length; breast cancer; biomarker; DNA methylation; MALDI TOF MS; quantitative real time PCR; Telomere length

Indexed keywords

PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER GRADING; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TELOMERE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TELOMERASE; TELOMERE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952009891     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.195     Document Type: Article

References (38)

1. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-573.
2. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256:271-282.
3. Wright WE, Shay JW. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat Med 2000;6:849-851.
4. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
5. Shay JW. Telomerase therapeutics: telomeres recognized as a DNA damage signal: commentary re: K. Kraemer et al., antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res., 9:3794-3800, 2003.
6. Clin Cancer Res 2003; 9 (10 Pt 1) : 3521-3525.
7. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003;21:2034-2043.
8. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-179.
9. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 2004;10:3317-3326.
10. Ohtani N, Yamakoshi K, Takahashi A, et al. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 2004;51:146-153.
11. 53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
12. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-645.
13. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005;37:961-976.
14. Zhang A, Wang J, Zheng B, et. Telomere attrition predominantly occurs in precursor lesions during in vivo carcinogenic process of the uterine cervix. Oncogene 2004;23:7441-7447.
15. Gisselsson D, Jonson T, Petersen A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA 2001;98:12683-12688.
16. Jacobs JJ, de Lange T. Significant role for p16INK4a in p53-independent telomere-directed senescence. Curr Biol 2004;14:2302-2308.
17. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002;30: e47.
18. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005;102:15785-15790.
19. Ehrich M, Turner J, Gibbs P, et al. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci USA 2008;105:4844-4849.
20. Radpour R, Haghighi MM, Fan AX, et al. Highthroughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidinespecific cleavage mass array on MALDI-TOF silicochip. Mol Cancer Res 2008;6:1702-1709.
21. Radpour R, Kohler C, Montazer Haghighi M, et al. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 2009;28:2969-2978.
22. Radpour R, Sikora M, Grussenmeyer T, et al. Simultaneous isolation of DNA, RNA, and proteins for genetic, epigenetic, transcriptomic, and proteomic analysis. J Proteome Res 2009;8:5264-5274.
23. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002;161:1961-1971.
24. Saldanha SN, Andrews LG, Tollefsbol TO. Assessment of telomere length and factors that contribute to its stability. Eur J Biochem 2003;270:389-403.
25. Lin KW, Yan J. The telomere length dynamic and methods of its assessment. J Cell Mol Med 2005;9:977-989.
26. Zakian VA. Telomeres: beginning to understand the end. Science 1995;270:1601-1607.
27. Rha SY, Park KH, Kim TS, et al. Changes of telomerase and telomere lengths in paired normal and cancer tissues of breast. Int J Oncol 1999;15:839-845.
28. Svenson U, Nordfjall K, Stegmayr B, et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 2008;68:3618-3623.
29. Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. Int J Cancer 2006;119:2255-2260.
30. Heaphy CM, Baumgartner KB, Bisoffi M, et al. Telomere DNA content predicts breast cancerfree survival interval. Clin Cancer Res 2007;13:7037-7043.
31. Kiyono T, Foster SA, Koop JI, et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84-88.
32. 16 (INK4a). Mol Cell 2004;14:501-513.
33. Mambo E, Chatterjee A, Xing M, et al. Tumor-specific changes in mtDNA content in human cancer. Int J Cancer 2005;116:920-924.
34. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev 2008 88:557-579.
35. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005;6:611-622.
36. Heaphy CM, Bisoffi M, Fordyce CA, et al. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 2006;119:108-116.
37. Dakubo GD, Jakupciak JP, Birch-Machin MA, et al. Clinical implications and utility of field cancerization. Cancer Cell Int 2007;7:2.
38. Meeker AK, Hicks JL, Gabrielson E, et al. Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol 2004;164:925-935.